DelSiTech

DelSiTech is a private, pre-revenue Finnish biotech leveraging its proprietary Silica Matrix platform to develop long-acting injectable formulations. The company's versatile technology enables controlled drug release over days to months, targeting improved patient adherence in metabolic disease and pain. Its business model combines internal pipeline development with technology licensing partnerships, positioning it as a potential enabler for next-generation sustained-release therapies.

Proprietary Silica Matrix technology: a biodegradable, silica-based injectable platform for sustained drug release over days to months. Compatible with small molecules, peptides, and biologics.

DelSiTech competes with other drug delivery technology companies (e.g., Alkermes, MedinCell, Luye Pharma) and the internal formulation capabilities of large pharmaceutical firms. Its key differentiator is the claimed broad compatibility of its silica-based platform with various molecule types, including sensitive biologics.